Distinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD
Liver International · 2026
DOI: 10.1111/liv.70873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Niharika Jakhar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Fatty Liver, Liver Diseases, Alcoholic, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisciplinary Centre for Clinical Research, RWTH Aachen University.
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction associated steatotic liver disease (MASLD) is the most prevalent liver disease, yet accurate early detection remains challenging. A particular diagnostic obstacle is distinguishing MASLD from metabolic dysfunction and alcohol‐related liver disease (MetALD), currently defined using clinically informed moderate alcohol consumption thresholds without biological validation. This study aimed to identify and externally validate plasma proteomic signatures associated with MASLD and assess whether proteomic profiles support a molecular distinction between MASLD and MetALD as currently defined.
Methods
We analysed plasma proteomic profiles using OLINK data from UK Biobank (UKB) participants with liver MRI. MASLD was defined as MRI‐PDFF ≥ 5% and metabolic dysfunction ( n = 165), MetALD ( n = 46) as MASLD with additional moderate alcohol intake and controls as PDFF < 5% ( n = 741).
Results
Compared to controls, participants with MASLD showed 17 upregulated and 3 downregulated proteins after Bonferroni correction (adjusted p < 0.05). Among upregulated proteins, leptin (LEP), fatty acid‐binding protein, liver (FABP1) and aminoacylase1 (ACY1) and among downregulated, insulin‐like growth factor‐binding protein 1 (IGFBP1) were externally validated in an independent cohort (clinicaltrials.gov NCT02520609, n = 47). Individuals with MetALD showed no significant proteomic distinction from MASLD. Although the small MetALD sample size may have limited detection of differences, direct differential expression analysis did not identify statistically significant differences between MASLD and MetALD under the current clinical thresholds.
Conclusions
MASLD was associated with a reproducible plasma proteomic signature enriched for proteins involved in lipid metabolism, inflammation and hormonal regulation. We did not identify a clear proteomic distinction between MASLD and MetALD under the current alcohol thresholds. However, this finding should be interpreted considering limited power and potential alcohol‐exposure misclassification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.
- Else Kroener Fresenius Center for Digital Health, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- German Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
ORCID-Profile: Niharika Jakhar, Tobias Seibel, Maria Mironova, Yazhou Chen, Thriveni B Raju, Juliette E Pearce, Ivan G Costa, Thomas Stiehl, Andreas Schuppert, Yaron Rotman, Carolin V Schneider
Förderung
- Interdisciplinary Centre for Clinical Research, RWTH Aachen University
Zitieren
APA
Jakhar, N., Seibel, T., Mironova, M., Meeßen, C., Clusmann, J., Chen, Y., Raju, T. B., Koop, P. H., Pearce, J. E., Costa, I. G., Stiehl, T., Schuppert, A., Schneider, K. M., Rotman, Y., & Schneider, C. V. (2026). Distinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD. Liver International. https://doi.org/10.1111/liv.70873
Vancouver
Jakhar N, Seibel T, Mironova M, Meeßen C, Clusmann J, Chen Y, et al. Distinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD. Liver International. 2026. doi:10.1111/liv.70873
BibTeX
@article{Jakhar2026,
author = {Jakhar, Niharika and Seibel, Tobias and Mironova, Maria and Meeßen, Corinna and Clusmann, Jan and Chen, Yazhou and Raju, Thriveni B and Koop, Paul-Henry and Pearce, Juliette E and Costa, Ivan G and Stiehl, Thomas and Schuppert, Andreas and Schneider, Kai Markus and Rotman, Yaron and Schneider, Carolin V},
title = {Distinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70873}
}
EUVIMED